英派药业致力于研发具有自主知识产权的靶向抗癌创新药，专注于合成致死作用机制。公司以DNA损伤修复通路（DDR）自主研发产品为基础，构建了全球生物医药公司中覆盖面最广的DDR产品组合之一，并且正在逐步拓展到更多的全新的合成致死靶点。
Location: China, Shanghai, Pudong
Employees: 51-200
Total raised: $40M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | West Fount... | westfounta... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.08.2018 | Series C | $30M | - |
| 22.02.2016 | Series B | $10M | - |
Mentions in press and media 12
| Date | Title | Description |
| 31.07.2026 | IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand | SHANGHAI, July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharmanovia, a global specialt... |
| 17.01.2025 | Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer | SHANGHAI, Jan. 17, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announc... |
| 22.04.2024 | Deals in brief: Temasek Trust entities fund five startups under Amplifier program, Pathgen scores funding, Diagnos acquires Asa Ren, and more | NewsDeals in brief: Jago Coffee raises USD 6 million in Series A round, Levelup merges with Zevero, Supabase acquires Oriole, and more Written by Jeff Chay Jago Coffee, Zevero, Supabase, and more led last week’s headlines: Jago Coffee, a Ja... |
| 01.06.2023 | Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors | SHANGHAI and HAYWARD, Calif., June 1, 2023 /PRNewswire/ -- IMPACT Therapeutics ("Impact"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, an... |
| 14.03.2022 | Impact Therapeutics Closes Series D1 Financing | Impact Therapeutics, a Shanghai, China-based biopharmaceutical company, raised an undisclosed amount in Series D1 funding. The round was led by Dingxin Capital, CCBT, C&D EMERGING CAPITAL, Bestride, Exome Asset Management with participa... |
| 14.03.2022 | Impact Therapeutics Announces Completion of Series D1 Financing | SHANGHAI, March 14, 2022 /PRNewswire/ -- IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of i... |
| 06.12.2021 | IMPACT 2021 R&D Day: Synthetic Lethality Provides a New Platform for Targeted Cancer Therapy | SHANGHAI, Dec. 6, 2021 /PRNewswire/ -- The 2nd R&D Day event of IMPACT Therapeutics (IMPACT) successfully took place in Shanghai on December 3rd (GMT+8). With the theme of "Synthetic Lethality: A New Platform for Targeted Therapy&q... |
| 03.12.2020 | News briefing: New senescent cell play launches with $12M; Junshi leads Series C+ infusion for Chinese synthetic lethality player | The idea of targeting senescent cells to treat age-related diseases is continuing to gather steam, and Khosla Ventures is helping get the latest play going with a $12 million seed round. Rubedo Life Sciences is focusing i... |
| 07.08.2018 | Impact Therapeutics raises $30m in Decheng Capital-led Series C round | Premium Chinese biopharmaceutical startup IMPACT Therapeutics has raised $30 million in a Series C round led by Decheng Capital and joined by return backer Lilly Asia Ventures. Continue reading this story with a subscription to DealStreetAs... |
| 03.08.2018 | Impact Therapeutics Raises $30M In Series C Financing | Impact Therapeutics, Inc., a Nanjing, China-based clinical-stage biopharmaceutical company dedicated to the discovery and development of medicine for the treatment of cancer and other life-threatening diseases, completed $30m series C finan... |
Show more